324 related articles for article (PubMed ID: 31125009)
1. The requirements for manufacturing highly active or sensitising drugs comparing Good Manufacturing Practices.
Petrelli F; Caraffa A; Scuri S; Grappasonni I; Magrini E; Cocchini A
Acta Biomed; 2019 May; 90(2):288-299. PubMed ID: 31125009
[TBL] [Abstract][Full Text] [Related]
2. Campaign manufacturing of highly active or sensitizing drugs: a comparison between the GMPs of various Regulatory Agencies.
Petrelli F; Scuri S; Grappasonni I; Nguyen CTT; Cocchini A; Magrini E; Caraffa A
Clin Ter; 2020; 170(1):e66-e73. PubMed ID: 31850487
[TBL] [Abstract][Full Text] [Related]
3. Quality of medicines: Deficiencies found by Brazilian Health Regulatory Agency (ANVISA) on good manufacturing practices international inspections.
Geyer ARC; Sousa VD; Silveira D
PLoS One; 2018; 13(8):e0202084. PubMed ID: 30089162
[TBL] [Abstract][Full Text] [Related]
4. Active pharmaceutical ingredients for antiretroviral treatment in low- and middle-income countries: a survey.
Fortunak JM; de Souza RO; Kulkarni AA; King CL; Ellison T; Miranda LS
Antivir Ther; 2014; 19 Suppl 3(0 3):15-29. PubMed ID: 25310430
[TBL] [Abstract][Full Text] [Related]
5. Overview of the European Medicines Agency's Development of Product-Specific Bioequivalence Guidelines.
Sullivan JO; Blake K; Berntgen M; Salmonson T; Welink J;
Clin Pharmacol Ther; 2018 Sep; 104(3):539-545. PubMed ID: 29319156
[TBL] [Abstract][Full Text] [Related]
6. [Pharmaceutical product quality control and good manufacturing practices].
Hiyama Y
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2010; (128):1-16. PubMed ID: 21381389
[TBL] [Abstract][Full Text] [Related]
7. Regulatory Aspects of Traditional Indian Medicines (TIM) in India and in International Purview.
Sharma AK; Pundarikakshudu K
J AOAC Int; 2019 Jul; 102(4):993-1002. PubMed ID: 30609950
[No Abstract] [Full Text] [Related]
8. Cost benefit of investment on quality in pharmaceutical manufacturing: WHO GMP pre- and post-certification of a Nigerian pharmaceutical manufacturer.
Anyakora C; Ekwunife O; Alozie F; Esuga M; Ukwuru J; Onya S; Nwokike J
BMC Health Serv Res; 2017 Sep; 17(1):665. PubMed ID: 28923044
[TBL] [Abstract][Full Text] [Related]
9. Provable Data Integrity in the Pharmaceutical Industry Based on Version Control Systems and the Blockchain.
Steinwandter V; Herwig C
PDA J Pharm Sci Technol; 2019; 73(4):373-390. PubMed ID: 30770485
[TBL] [Abstract][Full Text] [Related]
10. Regulatory and quality considerations for continuous manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
Allison G; Cain YT; Cooney C; Garcia T; Bizjak TG; Holte O; Jagota N; Komas B; Korakianiti E; Kourti D; Madurawe R; Morefield E; Montgomery F; Nasr M; Randolph W; Robert JL; Rudd D; Zezza D
J Pharm Sci; 2015 Mar; 104(3):803-12. PubMed ID: 25830179
[TBL] [Abstract][Full Text] [Related]
11. Institutional barriers and enablers to implementing and complying with internationally accepted quality standards in the local pharmaceutical industry of Pakistan: a qualitative study.
Tauqeer F; Myhr K; Gopinathan U
Health Policy Plan; 2019 Jul; 34(6):440-449. PubMed ID: 31302684
[TBL] [Abstract][Full Text] [Related]
12. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
World Health Organization
World Health Organ Tech Rep Ser; 2012; (970):1-235, back cover. PubMed ID: 22894011
[TBL] [Abstract][Full Text] [Related]
13. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-ninth report.
World Health Organization
World Health Organ Tech Rep Ser; 2015; (992):1-210, back cover. PubMed ID: 26118121
[TBL] [Abstract][Full Text] [Related]
14. Similarities and Differences of International Practices and Procedures for the Regulation for Active Substance Master Files/Drug Master Files of Human Use: Moving Toward Regulatory Convergence.
Matsuhama M; Takishita T; Kuribayashi R; Takagi K; Wakao R; Mikami K
J Pharm Pharm Sci; 2016; 19(2):290-301. PubMed ID: 27518176
[TBL] [Abstract][Full Text] [Related]
15. ICH: an exclusive club of drug regulatory agencies and drug companies imposing its rules on the rest of the world.
Prescrire Int; 2010 Aug; 19(108):183-6. PubMed ID: 20939460
[TBL] [Abstract][Full Text] [Related]
16. Recombinant drug development, regulation, and commercialization: an Indian industry perspective.
Sahoo N; Manchikanti P
BioDrugs; 2011 Apr; 25(2):105-13. PubMed ID: 21230010
[TBL] [Abstract][Full Text] [Related]
17. [Accession to the PIC/S and pharmaceutical quality system in Japan].
Katori N
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2014; (132):22-35. PubMed ID: 25707200
[TBL] [Abstract][Full Text] [Related]
18. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
World Health Organ Tech Rep Ser; 2003; 917():i-viii, 1-125, back cover. PubMed ID: 15024913
[TBL] [Abstract][Full Text] [Related]
19. WHO expert committee on specifications for pharmaceutical preparations. Fortieth report.
WHO Expert Committee on Specifications for Pharmaceutical Preparations
World Health Organ Tech Rep Ser; 2006; 937():1-461, back cover. PubMed ID: 16836287
[TBL] [Abstract][Full Text] [Related]
20. Harmonization of regulatory approaches for evaluating therapeutic equivalence and interchangeability of multisource drug products: workshop summary report.
Chen ML; Shah VP; Crommelin DJ; Shargel L; Bashaw D; Bhatti M; Blume H; Dressman J; Ducharme M; Fackler P; Hyslop T; Lutter L; Morais J; Ormsby E; Thomas S; Tsang YC; Velagapudi R; Yu LX
Eur J Pharm Sci; 2011 Nov; 44(4):506-13. PubMed ID: 21946259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
